Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer

AIM: In the registration trial, cabozantinib exposure ≥ 750 ng/mL correlated to improved tumor size reduction, response rate and progression free survival (PFS) in patients with metastatic renal cell cancer (mRCC). Because patients in routine care often differ from patients in clinical trials, we ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Krens, Stefanie D., van Erp, Nielka P., Groenland, Stefanie L., Moes, Dirk Jan A. R., Mulder, Sasja F., Desar, Ingrid M. E., van der Hulle, Tom, Steeghs, Neeltje, van Herpen, Carla M. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892746/
https://www.ncbi.nlm.nih.gov/pubmed/35236333
http://dx.doi.org/10.1186/s12885-022-09338-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892746/
https://www.ncbi.nlm.nih.gov/pubmed/35236333
http://dx.doi.org/10.1186/s12885-022-09338-1

Ejemplares similares